58905-21-8

Basic information

• Product Name: 1-(4-FLUOROPHENYL)-2-(1H-1,2,4-TRIAZOLE-1-YL)ETHANONE
• Synonyms: 1-(4-FLUOROPHENYL)-2-(1H-1,2,4-TRIAZOL-1-YL)ETHANONE;1-(4-FLUOROPHENYL)-2-(1H-1,2,4-TRIAZOLE-1-YL)ETHANONE;4''-Fluoro-2-(1H-1,2,4-triazol-1-)-ylacetophenone;1-(4-FLUOROPHENYL)-2-(1H-1,2,4-TRIAZOLE-1-YL)ETHANONE, 95+%;1-(4-Fluorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethan-1-one;α-(1H-1,2,4-Triazole-1-yl)-4'-fluoroacetophenone
• CAS NO: 58905-21-8
• Molecular Formula: C₁₀H₈FN₃O
• Molecular Weight: 205.19
• Mol File: 58905-21-8.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 396.111°C at 760 mmHg
• Flash Point: 193.361°C
• Appearance: /
• Density: 1.307g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.609
• PKA: 2.13±0.10(Predicted)
• CAS DataBase Reference: 1-(4-FLUOROPHENYL)-2-(1H-1,2,4-TRIAZOLE-1-YL)ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-FLUOROPHENYL)-2-(1H-1,2,4-TRIAZOLE-1-YL)ETHANONE(58905-21-8)
• EPA Substance Registry System: 1-(4-FLUOROPHENYL)-2-(1H-1,2,4-TRIAZOLE-1-YL)ETHANONE(58905-21-8)

Safety Data

• Hazardous Substances Data: 58905-21-8(Hazardous Substances Data)

Usage

General Description

1-(4-FLUOROPHENYL)-2-(1H-1,2,4-TRIAZOLE-1-YL)ETHANONE is an organic compound that possesses various important chemical functionalities including a fluorophenyl group, an ethanone group and a 1,2,4-triazole moiety. 1-(4-FLUOROPHENYL)-2-(1H-1,2,4-TRIAZOLE-1-YL)ETHANONE colours as white, crystalline, solid matter. Its molecular formula indicates that it contains 14 carbon atoms, 11 hydrogen atoms, 1 nitrogen atom, and 1 fluorine atom. The incorporation of a triazole ring and a fluorophenyl component may make it an important building block for the pharmaceuticals and agricultural chemicals synthesis. 1-(4-FLUOROPHENYL)-2-(1H-1,2,4-TRIAZOLE-1-YL)ETHANONE may also serve as an intermediate in a variety of industrial and laboratory chemical reactions due to its high reactivity.

InChI:InChI=1/C10H8FN3O/c11-9-3-1-8(2-4-9)10(15)5-14-7-12-6-13-14/h1-4,6-7H,5H2

Upstream product

• 288-88-0 1,2,4-Triazole 
• 403-29-2 2-bromo-4'-fluoroacetophenone 
• 288-36-8 1,2,3-triazole 
• 462-06-6 fluorobenzene 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 288-88-0 1,2,4-Triazole 
• 456-04-2 2-Chloro-4'-fluoroacetophenone 
• 128136-94-7 1-(4-Fluoro-phenyl)-2-[1,2,4]triazol-4-yl-ethanone 

Downstream Products

• 104940-89-8 1-(4-Fluoro-phenyl)-2-[1,2,4]triazol-1-yl-propenone 
• 168009-79-8 1-[2,3-epoxy-2-(4-fluorophenyl)propyl]-1H-1,2,4-triazole 
• 106325-08-0 epoxiconazole 
• 552849-88-4 α-(1H-1,2,4-triazolo-1-yl)-α-bromo-para-fluoroacetophenone 
• 299411-65-7 2-(4-fluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-trimethylsilylpent-4-en-2-ol 
• 936105-05-4 4-(4-fluoro-phenyl)-5-[1,2,4]triazol-1-yl-thiazol-2-ylamine 

Relevant articles and documents

Synthesis, optimization, antifungal activity, selectivity, and cyp51 binding of new 2-aryl-3-azolyl-1-indolyl-propan-2-ols

A series of 2-aryl-3-azolyl-1-indolyl-propan-2-ols was designed as new analogs of fluconazole (FLC) by replacing one of its two triazole moieties by an indole scaffold. Two different chemical approaches were then developed. The first one, in seven steps, involved the synthesis of the key intermediate 1-(1H-benzotriazol-1-yl)methyl-1H-indole and the final opening of oxiranes by imidazole or 1H-1,2,4-triazole. The second route allowed access to the target compounds in only three steps, this time with the ring opening by indole and analogs. Twenty azole derivatives were tested against Candida albicans and other Candida species. The enantiomers of the best anti-Candida compound, 2-(2,4-dichlorophenyl)-3-(1H-indol-1-yl)-1-(1H-1,2,4-triazol-1-yl)-propan-2-ol (8g), were analyzed by X-ray diffraction to determine their absolute configuration. The (?)-8g enantiomer (Minimum inhibitory concentration (MIC) = IC80 = 0.000256 μg/mL on C. albicans CA98001) was found with the S-absolute configuration. In contrast the (+)-8g enantiomer was found with the R-absolute configuration (MIC = 0.023 μg/mL on C. albicans CA98001). By comparison, the MIC value for FLC was determined as 0.020 μg/mL for the same clinical isolate. Additionally, molecular docking calculations and molecular dynamics simulations were carried out using a crystal structure of Candida albicans lanosterol 14α-demethylase (CaCYP51). The (?)-(S)-8g enantiomer aligned with the positioning of posaconazole within both the heme and access channel binding sites, which was consistent with its biological results. All target compounds have been also studied against human fetal lung fibroblast (MRC-5) cells. Finally, the selectivity of four compounds on a panel of human P450-dependent enzymes (CYP19, CYP17, CYP26A1, CYP11B1, and CYP11B2) was investigated.

Preparation method of epoxiconazole

The invention relates to a preparation method of epoxiconazole. The preparation method comprises the following steps: in the presence of an inert solvent, enabling fluoroacetophenone and a brominationreagent to react at -10 DEG C to 50 DEG C; carrying out

Novel alkylated azoles as potent antifungals

Fluconazole (FLC) is the drug of choice when it comes to treat fungal infections such as invasive candidiasis in humans. However, the widespread use of FLC has resulted in the development of resistance to this drug in various fungal strains and, simultaneously has occasioned the need for new antifungal agents. Herein, we report the synthesis of 27 new FLC derivatives along with their antifungal activity against a panel of 13 clinically relevant fungal strains. We also explore their toxicity against mammalian cells, their hemolytic activity, as well as their mechanism of action. Overall, many of our FLC derivatives exhibited broad-spectrum antifungal activity and all compounds displayed an MIC value of 0.03?μg/mL against at least one of the fungal strains tested. We also found them to be less hemolytic and less cytotoxic to mammalian cells than the FDA approved antifungal agent amphotericin B. Finally, we demonstrated with our best derivative that the mechanism of action of our compounds is the inhibition of the sterol 14α-demethylase enzyme involved in ergosterol biosynthesis.